Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (221-230 of 785) with videos related to

Pageof 79
Sort By:
Frontiers in Pharmacology|February 11, 2022
Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk MarkersSok Cin Tye, Sieta T de Vries, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|December 15, 2021
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular diseaseKohei Kaku, Christoph Wanner, Stefan D Anker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 15, 2011
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal RegistryMartin Wagner, David Ansell, David M Kent, et al.
Atherosclerosis|October 24, 2007
Transmission of oxLDL-derived lipid peroxide radicals into membranes of vascular cells is the main inducer of oxLDL-mediated oxidative stressThomas E Hansen-Hagge, Elke Baumeister, Tanja Bauer, et al.
Journal of Diabetes and Its Complications|October 18, 2023
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of riskRobert Weingold, Bernard Zinman, Michaela Mattheus, et al.
Artificial Organs|April 23, 2015
Pharmacokinetics of Certoparin During In Vitro and In Vivo DialysisDetlef H Krieter, Susanne Fink, Oliver Dorsch, et al.
Nephron|August 22, 2021
Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney InjuryDavid G Warnock, Javier A Neyra, Etienne Macedo, et al.
Diabetes, Obesity & Metabolism|September 24, 2021
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trialJoão Pedro Ferreira, Silvio E Inzucchi, Michaela Mattheus, et al.
Kidney International|October 10, 2002
Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?Peter Stenvinkel, Christoph Wanner, Thomas Metzger, et al.
European Journal of Heart Failure|July 28, 2011
Homoarginine, heart failure, and sudden cardiac death in haemodialysis patientsChristiane Drechsler, Andreas Meinitzer, Stefan Pilz, et al.
Pageof 79

Showing results (221-230 of 785) with videos related to

Sort By:
Pageof 79
Frontiers in Pharmacology|February 11, 2022
Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk MarkersSok Cin Tye, Sieta T de Vries, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|December 15, 2021
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular diseaseKohei Kaku, Christoph Wanner, Stefan D Anker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 15, 2011
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal RegistryMartin Wagner, David Ansell, David M Kent, et al.
Atherosclerosis|October 24, 2007
Transmission of oxLDL-derived lipid peroxide radicals into membranes of vascular cells is the main inducer of oxLDL-mediated oxidative stressThomas E Hansen-Hagge, Elke Baumeister, Tanja Bauer, et al.
Journal of Diabetes and Its Complications|October 18, 2023
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of riskRobert Weingold, Bernard Zinman, Michaela Mattheus, et al.
Artificial Organs|April 23, 2015
Pharmacokinetics of Certoparin During In Vitro and In Vivo DialysisDetlef H Krieter, Susanne Fink, Oliver Dorsch, et al.
Nephron|August 22, 2021
Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney InjuryDavid G Warnock, Javier A Neyra, Etienne Macedo, et al.
Diabetes, Obesity & Metabolism|September 24, 2021
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trialJoão Pedro Ferreira, Silvio E Inzucchi, Michaela Mattheus, et al.
Kidney International|October 10, 2002
Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?Peter Stenvinkel, Christoph Wanner, Thomas Metzger, et al.
European Journal of Heart Failure|July 28, 2011
Homoarginine, heart failure, and sudden cardiac death in haemodialysis patientsChristiane Drechsler, Andreas Meinitzer, Stefan Pilz, et al.
Pageof 79